Jun. 16 at 11:14 PM
$SIGA BARDA (Biomedical Advanced Research and Development Authority) does not have a specific, scheduled date for a new standalone smallpox antiviral Request for Proposal (RFP). Instead, BARDA procures smallpox antivirals continuously through the BARDA Broad Agency Announcement (BAA). The current BAA remains open for proposal submissions until September 25, 2028. [1, 2, 3, 4, 5]
BARDA maintains an ongoing, active portfolio for smallpox (orthopoxvirus) medical countermeasures. Rather than waiting for a specific large-scale solicitation, they continuously evaluate new proposals for antivirals that meet the following criteria: [1, 2]
Products belonging to a different product class or utilizing a novel mechanism of action compared to existing FDA-approved treatments (like TPOXX and TEMBEXA).
Antivirals with the potential to complement existing therapeutics or defend against resistant strains. [1, 2]
For companies or researchers developing an antiviral with different mechanisms of
